CFTR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL175502	0.61	18/20
SCHEMBL92374	0.57	7/20
SCHEMBL195591	0.54	7/20
SCHEMBL70873	0.50	7/20
SCHEMBL92571	0.49	7/20
SCHEMBL125591	0.53	5/20
SCHEMBL92574	0.49	5/20
SCHEMBL73753	0.46	5/20
SCHEMBL180990	0.45	5/20
SCHEMBL168545	0.56	4/20
SCHEMBL171102	0.51	4/20
SCHEMBL195076	0.49	4/20
SCHEMBL72972	0.48	4/20
SCHEMBL92355	0.48	4/20
SCHEMBL155135	0.48	4/20
SCHEMBL182393	0.47	4/20
SCHEMBL267568	0.46	4/20
SCHEMBL204099	0.43	4/20
SCHEMBL131733	0.40	4/20
SCHEMBL11258	0.37	4/20

Clinical trials — most relevant to CFTR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis	PHASE3	COMPLETED
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation	PHASE3	COMPLETED
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation	PHASE3	COMPLETED
Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects	PHASE1/PHASE2	COMPLETED
Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators	PHASE2	COMPLETED
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis	PHASE1	COMPLETED
Regional Monitoring of CF Lung Disease	EARLY_PHASE1	RECRUITING
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)	nan	COMPLETED
Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis	nan	COMPLETED
Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis (UNLOCk)	nan	COMPLETED
Energy Balance and Weight Gain With Ivacaftor Treatment	nan	COMPLETED
Comparison Between Ultra-low-dose Computed Tomography and Lung MRI in Cystic Fibrosis	nan	COMPLETED
Organoid Study R334W	nan	WITHDRAWN
Comparative Effects of Mechanical and Manual Airway Clearance Techniques in Cystic Fibrosis	nan	NOT_YET_RECRUITING
Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls	nan	COMPLETED
Evaluation of New Device for Beta-adrenergic Sweat Test in the Context of Stratification of Patient With Cystic Fibrosis	nan	RECRUITING
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis	nan	UNKNOWN
Gene Modifiers of Cystic Fibrosis Lung Disease	nan	ACTIVE_NOT_RECRUITING
Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations	nan	COMPLETED
Clinical and Genetic Profile of Pediatric Patients With Cystic Fibrosis in Sohag.	nan	COMPLETED
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators	nan	RECRUITING
EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis	nan	COMPLETED
New Markers of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Sweat	nan	UNKNOWN
CFTR Modulators and Gastrointestinal Complications	nan	COMPLETED
Assessment of Patients Not Concluded After Neonatal Screening of Cystic Fibrosis.	nan	NOT_YET_RECRUITING
The PROMISE Pediatric Study 6 to 11 Years Old	nan	COMPLETED
Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects	nan	COMPLETED
Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CFTR binder may also engage these)

Protein	Name	Similarity
Q9TUQ2	—	1.000	Q9TUQ2 →
Q7JII8	—	1.000	Q7JII8 →
Q09YH0	—	1.000	Q09YH0 →
Q2QLE5	—	1.000	Q2QLE5 →
Q2QLB4	—	1.000	Q2QLB4 →
Q9TSP5	—	1.000	Q9TSP5 →
Q09YK5	—	1.000	Q09YK5 →
Q00554	—	1.000	Q00554 →
Q2QLH0	—	1.000	Q2QLH0 →
Q2IBF6	—	1.000	Q2IBF6 →
Q07DX5	—	1.000	Q07DX5 →
Q2IBE4	—	1.000	Q2IBE4 →
P35071	—	1.000	P35071 →
Q07E16	—	1.000	Q07E16 →
Q07DY5	—	1.000	Q07DY5 →
Q00PJ2	—	1.000	Q00PJ2 →
Q2QL83	—	1.000	Q2QL83 →
Q2QLF9	—	1.000	Q2QLF9 →
Q2QLC5	—	1.000	Q2QLC5 →
Q2IBB3	—	1.000	Q2IBB3 →
P26361	—	1.000	P26361 →
Q00555	—	1.000	Q00555 →
Q07DV2	—	1.000	Q07DV2 →
Q2IBA1	—	1.000	Q2IBA1 →
Q2QLA3	—	1.000	Q2QLA3 →
Q7JII7	—	1.000	Q7JII7 →
Q00553	—	1.000	Q00553 →
Q00552	—	1.000	Q00552 →
Q09YJ4	—	1.000	Q09YJ4 →
Q108U0	—	1.000	Q108U0 →